Enliven Therapeutics (ELVN) Other Working Capital Changes (2019)
Enliven Therapeutics (ELVN) posted Other Working Capital Changes of -$369000.0 for Q4 2019.
Enliven Therapeutics (ELVN) Other Working Capital Changes (2019) Analysis & Trends
Enliven Therapeutics has reported Other Working Capital Changes for 1 years, with the latest figure at -$369000.0 in Q4 2019.
- Quarterly Other Working Capital Changes fell 40.58% year-over-year to -$97000.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$365000.0 (down 13.71% YoY) and the FY2025 annual result came in at -$337000.0, down 0.6% from the prior year.
- Other Working Capital Changes eased to -$97000.0 in Q1 2026 per ELVN's latest filing, from -$91000.0 in the prior quarter.
- Over five years, Other Working Capital Changes peaked at $1000.0 in Q4 2022 and troughed at -$229000.0 in Q3 2023.
- A 5-year average of -$77000.0 and a median of -$83500.0 in 2024 frame the typical range for Other Working Capital Changes.
- The widest YoY moves for Other Working Capital Changes: up 63.32% in 2024, down 8200.0% in 2024.
- Over 5 years, Other Working Capital Changes stood at $1000.0 in 2022, then plunged by 8000.0% to -$79000.0 in 2023, then declined by 7.59% to -$85000.0 in 2024, then decreased by 7.06% to -$91000.0 in 2025, then slipped by 6.59% to -$97000.0 in 2026.
- According to Business Quant data, Other Working Capital Changes over the past three periods registered -$97000.0, -$91000.0, and -$90000.0 for Q1 2026, Q4 2025, and Q3 2025 respectively.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn |
| 10 | Enliven Therapeutics | 4.31 Bn | 3.41 Bn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2019 | -369,000.00 |
| Dec 31, 2019 | -369,000.00 |
| Dec 31, 2019 | -369,000.00 |